BUCCIONI, Michela
 Distribuzione geografica
Continente #
NA - Nord America 12.798
EU - Europa 6.385
AS - Asia 4.533
SA - Sud America 558
AF - Africa 185
Continente sconosciuto - Info sul continente non disponibili 31
OC - Oceania 11
Totale 24.501
Nazione #
US - Stati Uniti d'America 12.441
CN - Cina 1.754
SG - Singapore 1.362
RU - Federazione Russa 1.292
PL - Polonia 1.283
IT - Italia 1.110
DE - Germania 711
BR - Brasile 449
GB - Regno Unito 408
HK - Hong Kong 387
FR - Francia 381
VN - Vietnam 355
UA - Ucraina 328
CA - Canada 287
SE - Svezia 270
FI - Finlandia 248
KR - Corea 150
TR - Turchia 136
ZA - Sudafrica 124
IN - India 91
IE - Irlanda 87
JP - Giappone 78
BE - Belgio 54
MX - Messico 52
AR - Argentina 48
NL - Olanda 47
BD - Bangladesh 35
EU - Europa 31
ES - Italia 29
CZ - Repubblica Ceca 23
IR - Iran 23
PK - Pakistan 23
AT - Austria 21
TW - Taiwan 18
EC - Ecuador 17
IQ - Iraq 17
RO - Romania 17
AE - Emirati Arabi Uniti 14
LT - Lituania 12
TN - Tunisia 12
CH - Svizzera 11
KE - Kenya 11
RS - Serbia 11
EG - Egitto 10
AZ - Azerbaigian 9
CO - Colombia 9
IL - Israele 9
PE - Perù 9
PY - Paraguay 9
AU - Australia 8
ID - Indonesia 8
SA - Arabia Saudita 8
CL - Cile 7
JO - Giordania 7
UZ - Uzbekistan 7
VE - Venezuela 7
MA - Marocco 6
PH - Filippine 6
AM - Armenia 5
BG - Bulgaria 5
BY - Bielorussia 5
DK - Danimarca 5
DZ - Algeria 5
LB - Libano 5
OM - Oman 5
AL - Albania 4
CI - Costa d'Avorio 4
GE - Georgia 4
HR - Croazia 4
NP - Nepal 4
DO - Repubblica Dominicana 3
ET - Etiopia 3
GR - Grecia 3
HN - Honduras 3
KW - Kuwait 3
MY - Malesia 3
NO - Norvegia 3
SI - Slovenia 3
TH - Thailandia 3
BO - Bolivia 2
CR - Costa Rica 2
HU - Ungheria 2
JM - Giamaica 2
KH - Cambogia 2
MU - Mauritius 2
PA - Panama 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
AS - Samoa Americane 1
BA - Bosnia-Erzegovina 1
CM - Camerun 1
DM - Dominica 1
EE - Estonia 1
GD - Grenada 1
GM - Gambi 1
GT - Guatemala 1
IS - Islanda 1
KI - Kiribati 1
KZ - Kazakistan 1
Totale 24.490
Città #
Fairfield 1.156
Warsaw 1.041
Ashburn 1.025
Woodbridge 977
Dallas 823
Jacksonville 760
Singapore 693
Houston 641
San Jose 594
Chandler 592
Seattle 484
Wilmington 469
Ann Arbor 443
Cambridge 417
Hong Kong 363
Boardman 338
Beijing 286
Camerino 255
Kraków 229
Nanjing 213
Los Angeles 195
Toronto 192
Council Bluffs 187
The Dalles 170
New York 150
Helsinki 141
Seoul 124
Columbus 113
Ho Chi Minh City 113
Tongling 113
San Mateo 112
Johannesburg 109
Lawrence 107
Princeton 107
Dearborn 105
Istanbul 105
Lauterbourg 96
Ogden 96
Dublin 86
Nanchang 84
Moscow 82
Buffalo 81
London 81
Düsseldorf 79
Shanghai 78
Santa Clara 77
Guangzhou 70
Hanoi 69
San Diego 68
Chicago 67
Milan 67
Munich 65
Lachine 64
Tokyo 61
Frankfurt am Main 57
São Paulo 54
Brussels 51
Kunming 50
Edinburgh 44
Shenyang 43
St Louis 43
Orem 41
Tianjin 38
Centro 34
Rome 34
Jiaxing 33
Hebei 29
Philadelphia 29
Hefei 28
Wuhan 28
Denver 27
Dong Ket 27
Hangzhou 26
Brooklyn 25
Trieste 25
Chennai 24
Mexico City 24
Boston 23
Ningbo 23
Changsha 22
Manchester 22
San Francisco 22
Norwalk 21
Phoenix 21
Poplar 21
Jinan 20
Nuremberg 20
Redwood City 20
Atlanta 19
Turku 18
Amsterdam 17
Bremen 17
Haiphong 17
Falls Church 16
Rio de Janeiro 16
Venezia 16
Brno 15
Da Nang 15
Redondo Beach 15
Tampa 15
Totale 16.558
Nome #
1,3-Dioxolane-based ligands incorporating a lactam or imide moiety: Structure-affinity/activity relationship at α1-adrenoceptor subtypes and at 5-HT1A receptors. 611
1,2,4-Benzothiadiazine derivatives as alpha1 and 5-HT1A receptor ligands 593
1,3-Dioxane as a scaffold for potent and selective 5-HT1AR agonist with in-vivo anxiolytic, anti-depressant and anti-nociceptive activity 531
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 450
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 403
Overview on Radiolabel-Free in Vitro Assays for GPCRs 399
Pharmacological characterization of the GPR17 receptor dual profile 393
GPR17 receptor modulators and their therapeutic implications: review of recent patents 389
The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype 384
The G Protein-Coupled Receptor GPR17: Overview and Update 370
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 355
Blue honeysuckle fruit (Lonicera caerulea L.) from eastern Russia: phenolic composition, nutritional value and biological activities of its polar extracts 348
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 325
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands 293
Polar extracts from the berry-like fruits of Hypericum androsaemum L. as a promising ingredient in skin care formulations 293
Acetylshikonin isolated from Lithospermum erythrorhizon roots inhibits dihydrofolate reductase and hampers autochthonous mammary carcinogenesis in Δ16HER2 transgenic mice 286
Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia 282
Synthesis and pharmacological profile of a series of 1-substituted-2-carbonyl derivatives of diphenidol: novel M4 muscarinic receptor antagonists 274
Neuropeptide S Receptor: recent updates on non-peptide antagonist discovery 274
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 265
Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists 264
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 264
Levels of polychlorinated biphenyls in fish and shellfish from the Adriatic Sea 262
Synthesis and alpha1-adrenoceptor antagonist activity of derivatives and isosters of the furan portion of (+)-cyclazosin 249
Antiproliferative Evaluation of Isofuranodiene on Breast and Prostate Cancer Cell Lines 244
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 244
Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain 240
Choline-Containing Phospholipids: Structure-Activity Relationships Versus Therapeutic Applications. 237
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 236
Purinergic P2X receptors: Structural models and analysis of ligand-target interaction 234
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 234
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A(2A) and A(2B) receptors ligands 233
Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17 232
“Third Joint Italian-German Purine Club Meeting - Purinergic Receptors: New Frontiers for Novel Therapies” 230
(+)-Cyclazosin, a selective alpha1B-adrenoceptor antagonist: Functional evaluation in rat and rabbit tissues 225
New sensible method to quantize the intestinal absorption of receptor ligands 224
Chiral analogues of (+)-cyclazosin as potent α1B-adrenoceptor selective antagonist 224
(+)-Cyclazosin derivatives as α1-adrenoceptor antagonists 223
Structure-Activity Relatioships Among Novel Phenoxybenzamine-Related Beta-Chloroethylamines. 221
Synthesis and structure-activity relationships of novel arylpiperazines as potent antagonists of α1-adrenoceptor 220
Deoxamuscaroneoxime Devatives as useful Muscarinic Aginist to Explore the Muscarinic Subsite: Demox, Amodulator of Orthosteric and Allosteric Site at Cardiac Muscarinic M2 Receptors. 218
Molecular modeling studies on the human neuropeptide S receptor and its antagonists. 218
(2,2-Diphenyl-[1,3]oxathiolan-5-ylmethyl)-(3-phenyl-propyl)-amine: a Potent and Selective 5-HT1A Receptor Agonist 218
Molecular modeling study on potent and selective adenosine A3 receptor agonists. 217
Evidence for the existence of a specific G protein-coupled receptor activated by guanosine 217
Muscarinic subtype affinity and functional activity profile of 1-methyl-2-(2-methyl-1,3-dioxolan-4-yl)pyrrolidine and 1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine derivatives 214
Analogues of Prazosin That Bear a Benextramine-Related Polyamine Backbone Exhibit Different Antagonism toward alpha1-Adrenoceptor Subtypes 213
A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity 213
Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity 212
Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1 210
Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch 208
Rapid novel divergent synthesis and muscarinic agonist profile of all four optical isomers of N,N,N-trimethyl(6-methyl-1,4-dioxan-2-yl)methanaminium iodide. 207
Synthesis and antagonistic activity at muscarinic receptor subtypes of some derivatives of diphenidol 206
Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells 203
Identification of alpha(1)-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens 202
Discovery of a new series of 5-HT1A receptor agonists 202
The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors 198
Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor 198
Innovative functional cAMP assay: application to the pharmacological characterization of GPR17 195
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists 193
Molecular modulation of muscarinic antagonists. Synthesis and affinity profile of 2,2-diphenyl-2-ethylthio-acetic acid esters designed to probe the binding site cavity. 192
Synthesis and pharmacological characterization of chiral pyrrolidinylfuran derivatives: The discovery of new functionally selective muscarinic agonists 191
Synthesis, affinity profile, and functional activity of muscarinic antagonists with a 1-methyl-2-(2,2-alkylaryl-1,3-oxathiolan-5-yl)pyrrolidine structure 188
Human adenosine A3 receptor as selective target of new 2-aralkynyl-N6-methyl-MECA derivatives 188
Molecular modulation of muscarinic antagonists. Synthesis and pharmacological profile of 2,2-diphenyl-2-ethylthioacetic and 3,3-diphenyl-3-ethylthiopropionic acid derivatives characterized by a dipeptide spacer. 185
Functional cAMP assay optimization at CHO cells expressing A2A adenosine receptors and stably transfected with firefly luciferase biosensor 183
A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable? 183
Highly chiral muscarinic ligands: The discovery of (2S,2 ' R,3 ' S,5 ' R)-1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine 3-sulfoxide methyl iodide, a potent, functionally selective, M-2 partial agonist 182
Dioxane and Oxathiane Nuclei: Suitable Substructures for Muscarinic Agonists 180
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4 chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subtypes in the regulation of human PC-3 prostate cancer cell apoptosis and proliferation 178
Synthesis, Affinity Profile and Functional Activity of Potent Chiral Muscarinic Antagonists with a Pyrrolidinylfuran Structure 177
Polyamines may modulate both G protein-coupled receptors and G proteins. 176
Adenosine Receptors as Neuroinflammation Modulators: Role of A1 Agonists and A2A Antagonists 176
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease 174
Structure-activity relationships among novel phenoxybenzamine-related beta-chloroethylamines 169
Adenine derivatives as inhibitors of the casein kinase CK1delta enzyme 166
Outstanding insecticidal activity and sublethal effects of Carlina acaulis root essential oil on the housefly, Musca domestica, with insights on its toxicity on human cells 165
Synthesis and cholinergic affinity of diastereomeric and enantiomeric isomers of 1-methyl-2-(2-methyl-1,3-dioxolan-4-yl)pyrrolidine, 1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine and of their iodomethylates. 164
High affinity ligands and potent antagonists for the α1D-adrenergic receptor. Novel 3,8-disubstituted [1]benzothieno[3,2-d]pyrimidine derivatives 164
In vitro metabolism studies of new adenosine A(2A) receptor antagonists 163
Purinergic P2X receptors: Structural models and analysis of receptor-ligand interaction 162
Muscarinic antagonists with multiple stereocenters: Synthesis, affinity profile and functional activity of isomeric 1-methyl-2-(2,2-alkylaryl-1,3-oxathiolan-5-yl) pyrrolidine sulfoxide derivatives 160
New pyrimido[5,4-b]indoles and [1]benzothieno[3,2-d]pyrimidines: High affinity ligands for the alpha-adrenoceptor subtypes 159
(+)-Cyclazosin Derivatives as alpha1-Adrenoceptor Antagonists 159
Synthesis and α(1)-adrenoceptor antagonist activity of tamsulosin analogues 156
null 149
GTP-Eu binding assay optimization for the adenosine A3 receptor ligands screening 149
New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases 149
New purine derivatives as P2X3 receptor antagonists 147
Structure-Activity Relationships in 2,2-Diphenyl-2-ethylthioacetic Acid Esters: Unexpected Agonist Activity in a Series of Muscarinic Antagonists. 147
Adenosine A2A Receptor Antagonists: Chemistry, SARs, and Therapeutic Potential 146
A2A adenosine receptor ligands: effects on alcohol intake in alcohol-preferring rats 146
Synthesis and biological evaluation of 2-alkynyl-N6-methyl-5'-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A(3) receptor 143
Existence of snoRNA, microRNA, piRNA characteristics in a novel non-coding RNA: x-ncRNA and its biological implication in Homo sapiens 141
“Dual Anta-Inhibitors” of the A2A Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling Studies 139
Development of new chromatographic tools based on Adenosine A2A subtype receptor for ligand characterization and screening by FAC-MS 136
Structure–activity relationships of methoctramine-relatedpolyamines as muscarinic antagonist: Effect of replacing theinner polymethylene chain with cyclic moieties 135
Anticancer activity study of A3 adenosine receptor agonists 135
Butter oil (ghee) enrichment with aromatic plants: Chemical characterization and effects on fibroblast migration in an in-vitro wound healing model 134
Combined therapy of A1AR agonists and A2AAR antagonists in neuroinflammation 133
Totale 22.889
Categoria #
all - tutte 97.346
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 97.346


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021229 0 0 0 0 0 0 0 0 0 0 0 229
2021/20221.424 136 347 40 55 64 48 84 112 105 148 130 155
2022/20231.496 171 93 60 246 149 193 10 98 240 73 120 43
2023/20241.239 161 65 73 49 46 108 63 95 139 43 49 348
2024/20254.005 149 86 334 191 134 220 453 1.037 303 270 291 537
2025/20266.688 382 413 1.136 829 722 471 995 444 410 419 369 98
Totale 24.945